Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AB102

Other · developed by Arcus Biosciences

Phase 1 Most advanced trial
RCUS Developer
1 Registered trials

What is AB102?

AB102 is an agent administered orally, according to a trial registry entry, studied in healthy volunteers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Developer
Arcus Biosciences, Inc. (RCUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07662057 Phase 1 Healthy Volunteers Recruiting RCUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Arcus Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.

Follow RCUS, the company behind AB102

See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RCUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.